A phase 1/2 trial found that a chemotherapy-free combo of mosunetuzumab and polatuzumab vedotin achieved a complete response in over half of older, unfit patients with newly diagnosed DLBCL. With a 2-year overall survival of 62.4%, the results are encouraging — though infections, especially COVID-19-related deaths among frail patients, remain a serious concern.
For older or frail patients with diffuse large B-cell lymphoma (DLBCL) who can't tolerate standard chemotherapy, treatment options have historically been limited — with about 25% of those aged 80+ receiving no lymphoma treatment at all. A new phase 1/2 trial published in Blood tested a chemotherapy-free combination of subcutaneous mosunetuzumab (a bispecific antibody) and polatuzumab vedotin (an antibody-drug conjugate) as a first-line approach in 101 previously untreated patients with a median age of 81.
The results were promising: 61.4% of patients achieved an objective response at end of treatment, and 56.4% achieved a complete response. Median progression-free survival reached 32.1 months, and 72.1% of complete responders remained in remission at 2 years.
By the Numbers:
Why it matters: This study offers a viable, chemo-free treatment path for a population that has long been underserved. While infection risk — particularly COVID-19 — remains a critical safety concern in frail patients, the durable responses seen here suggest that bispecific antibody and antibody-drug conjugate combinations could reshape first-line care for elderly lymphoma patients.
